Clinical Research Directory
Browse clinical research sites, groups, and studies.
Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure
Sponsor: Mansoura University
Summary
This study investigates the comparative clinical outcomes of dapagliflozin, an SGLT-2 inhibitor, versus acetazolamide, a carbonic anhydrase inhibitor, in patients hospitalized with acute heart failure (AHF). The trial aims to assess the effectiveness of these drugs in improving natriuretic and diuretic responses and shortening hospital stays. Dapagliflozin and acetazolamide will be added to standard loop diuretic therapy, and their safety profiles will be evaluated to identify potential side effects. This research seeks to provide evidence for incorporating these drugs into AHF management, with the potential to improve clinical outcomes.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2024-08-15
Completion Date
2025-08-01
Last Updated
2025-01-20
Healthy Volunteers
No
Conditions
Interventions
Dapagliflozin 10mg
Dapagliflozin 10 mg is a medication classified as a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
Acetazolamide 500mg
Acetazolamide 500 mg is a medication classified as a carbonic anhydrase inhibitor.
Locations (1)
Noha Mansour
Al Mansurah, Egypt